Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes the SWITCH 2 randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 318, Issue 1, 2017, Pages 45-56

  Wysham, Carol ^a   Bhargava, Anuj ^b   Chaykin, Louis ^c   De La Rosa, Raymond ^d   Handelsman, Yehuda ^e   Troelsen, Lone N ^f   Kvist, Kajsa ^f   Norwood, Paul ^g  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Iowa Diabetes and Endocrinology Center   (United States)

^c Meridien Research   (United States)

^d Paducah Kentucky   (United States)

^e Metabolic Institute of America   (United States)

^f NOVO NORDISK A S   (Denmark)

^g Valley Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; RECOMBINANT HUMAN INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; LONG ACTING INSULIN;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; UPPER RESPIRATORY TRACT INFECTION; AGED; ANALYSIS; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; HYPOGLYCEMIA; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; RISK FACTORS;

EID: 85021844844     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.7117     Document Type: Article

References (28)

1. Frier BM. How hypoglycaemia can affect the life of a person with diabetes. DiabetesMetab Res Rev. 2008;24(2):87-92.
2. Leiter LA, Yale JF, Chiasson JL, Harris S, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes. 2005; 29(3):186-192.
3. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321 (7258):405-412.
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359 (15):1577-1589.
5. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
6. Hermansen K, DaviesM, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-To-Target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006; 29(6):1269-1274.
7. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28(10): 1569-1581.
8. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-To-Target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26 (11):3080-3086.
9. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53(6): 1614-1620.
10. Haahr H, HeiseT.Areview of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53(9):787-800.
11. Novo Nordisk. Tresiba demonstrated lower day-To-day and within-day variability in glucose-lowering effect compared with insulin glargine U300 [press release]. November 12, 2016. http://www.novonordisk.com/media/news-details .2056385.html. Accessed January 16, 2017.
12. Garber AJ, King AB, Del Prato S, et al; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): A phase 3, randomised, open-label, treat-To-Target non-inferiority trial. Lancet. 2012;379(9825):1498-1507.
13. Zinman B, Philis-Tsimikas A, Cariou B, et al; NN1250-3579 (BEGIN Once Long) Trial Investigators. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: A 1-year, randomized, treat-To-Target trial (BEGIN Once Long). Diabetes Care. 2012;35(12): 2464-2471.
14. Vora J, Christensen T, Rana A, Bain SC. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: Ameta-Analysis of endpoints in phase 3a trials. Diabetes Ther. 2014;5(2):435-446.
15. Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: A pre-planned meta-Analysis of phase 3 trials. Diabetes Obes Metab. 2013;15(2):175-184.
16. World Medical Association.World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194.
17. International Conference of Harmonisation. ICH harmonised tripartite guideline: guideline for Good Clinical Practice.May 1, 1996. http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/good-clinical-practice.html. Accessed January 16, 2016.
18. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36 (5):1384-1395.
19. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50(6):1140-1147.
20. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: A report from the American Diabetes AssociationWorkgroup on Hypoglycemia. Diabetes Care. 2005;28(5):1245-1249.
21. Donnelly LA, Morris AD, Frier BM, et al; DARTS/MEMO Collaboration. Frequency and predictors of hypoglycaemia in type 1 and insulin-Treated type 2 diabetes: A population-based study. Diabet Med. 2005;22(6):749-755.
22. Leese GP, Wang J, Broomhall J, et al; DARTS/MEMO Collaboration. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: A population-based study of health service resource use. Diabetes Care. 2003;26(4):1176-1180.
23. Curkendall SM, Zhang B, Oh KS, Williams SA, Pollack MF, Graham J. Incidence and cost of hypoglycemia among patients with type 2 diabetes in the United States: Analysis of a health insurance database. J Clin Outcomes Manag. 2011;18(10):455-462.
24. Hammer M, LammertM, Mejías SM, KernW, Frier BM. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12 (4):281-290.
25. Becker RHA, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 Units mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units mL-1. Diabetes Care. 2015;38(4):637-643.
26. Yki-Järvinen H, Bergenstal R, Ziemen M, et al; EDITION 2 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37(12):3235-3243.
27. Sanovi-Aventis. Toujeo prescribing information. 2015. https://www.toujeo.com/. Accessed January 16, 2017.
28. American Diabetes Association. Standards of medical care in diabetes-2017. Diabetes Care. 2017; 40(suppl 1):S1-S133.